|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 12.49 AUD | +0.08% |
|
-0.24% | -32.89% |
| 08/04 | Neuren Pharmaceuticals Says Rett Syndrome Drug DAYBUE STIX Widely Available in the US | MT |
| 08/04 | Neuren Pharmaceuticals says Daybue Stix now broadly available in US for Rett syndrome | RE |
| Capitalization | 1.58B 1.14B 962M 885M 838M 1.55B 105B 10.37B 4.07B 50.94B 4.26B 4.17B 180B | P/E ratio 2026 * |
101x | P/E ratio 2027 * | 25.1x |
|---|---|---|---|---|---|
| Enterprise value | 1.3B 938M 795M 731M 692M 1.28B 86.79B 8.56B 3.36B 42.07B 3.52B 3.45B 148B | EV / Sales 2026 * |
17.3x | EV / Sales 2027 * | 8.5x |
| Free-Float |
83.48% | Yield 2026 * |
0.27% | Yield 2027 * | 1.52% |
Last Transcript: Neuren Pharmaceuticals Limited
| 1 day | +0.08% | ||
| 1 week | -0.24% | ||
| Current month | +5.76% | ||
| 1 month | +9.56% | ||
| 3 months | -34.74% | ||
| 6 months | -39.52% | ||
| Current year | -32.89% |
| 1 week | 12.01 |  | 12.71 |
| 1 month | 11 | | 13.22 |
| Current year | 11 | | 21.04 |
| 1 year | 10.32 | | 22.98 |
| 3 years | 8.61 | | 25.95 |
| 5 years | 1.2 | | 25.95 |
| 10 years | 0.82 | | 25.95 |
| Manager | Title | Age | Since |
|---|---|---|---|
Jon Pilcher
CEO | Chief Executive Officer | 60 | 27/05/2020 |
Lauren Frazer
DFI | Director of Finance/CFO | - | 01/08/2020 |
Liza Squires
CTO | Chief Tech/Sci/R&D Officer | - | 08/07/2022 |
| Director | Title | Age | Since |
|---|---|---|---|
Jon Pilcher
BRD | Director/Board Member | 60 | 14/06/2021 |
Dianne Angus
BRD | Director/Board Member | 65 | 05/07/2018 |
Patrick Davies
CHM | Chairman | 59 | 27/05/2020 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.08% | -0.24% | +18.61% | -7.14% | 1.13B | |
| +2.55% | -1.32% | +10.37% | +148.97% | 809B | |
| -0.15% | -1.79% | +48.71% | +41.35% | 565B | |
| -0.29% | +0.21% | +20.46% | +29.28% | 370B | |
| -0.35% | 0.00% | +23.47% | +13.55% | 320B | |
| +1.72% | -0.74% | +49.33% | +27.86% | 312B | |
| +1.19% | -2.41% | +31.10% | +34.87% | 286B | |
| +3.13% | -1.94% | +52.65% | +3.53% | 285B | |
| +1.69% | +1.22% | +28.13% | +43.23% | 189B | |
| +1.24% | +8.21% | -38.18% | -55.23% | 180B | |
| Average | +1.08% | -0.67% | +24.47% | +28.03% | 331.55B | |
| Weighted average by Cap. | +1.23% | -1.26% | +26.76% | +53.35% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 75.24M 54.08M 45.81M 42.15M 39.9M 73.94M 5B 494M 194M 2.43B 203M 199M 8.55B | 152M 109M 92.54M 85.15M 80.59M 149M 10.11B 997M 391M 4.9B 410M 401M 17.27B |
| Net income | 14.54M 10.45M 8.85M 8.15M 7.71M 14.29M 967M 95.41M 37.41M 469M 39.21M 38.39M 1.65B | 60.1M 43.2M 36.6M 33.67M 31.87M 59.06M 4B 394M 155M 1.94B 162M 159M 6.83B |
| Net Debt | -275M -198M -168M -154M -146M -270M -18.3B -1.81B -708M -8.87B -742M -726M -31.27B | -288M -207M -175M -161M -152M -283M -19.13B -1.89B -740M -9.27B -775M -759M -32.68B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 17/04/26 | 12.49 $ | +0.08% | 254,622 |
| 16/04/26 | 12.48 $ | -0.08% | 285,507 |
| 15/04/26 | 12.49 $ | +1.05% | 414,922 |
| 14/04/26 | 12.36 $ | +1.06% | 277,046 |
| 13/04/26 | 12.23 $ | -2.32% | 206,401 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- NEU Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition